{"transactions":[{"id":726305,"issuer":{"id":5316,"kind":"organization","name":"MapLight Therapeutics, Inc.","symbol":"MPLT"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-25T22:01:35.000Z","date":"2026-06-23","kind":"grant","planned":false,"acquired":true,"shares":29804,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents a stock option granted pursuant to the Plan. The shares subject to this stock option will vest in three equal annual installments beginning on June 23, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy."}],"balance_after":29804,"derivative":{"exercise_price":28.64,"expiration_date":"2036-06-22","underlying":"Voting Common Stock","underlying_shares":29804},"source":{"system":"sec-edgar","filing":"0001435618-26-000011","document":"form4-06252026_100631.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000143561826000011/form4-06252026_100631.xml","form_type":"4"}},{"id":726304,"issuer":{"id":5316,"kind":"organization","name":"MapLight Therapeutics, Inc.","symbol":"MPLT"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Stock","published_at":"2026-06-25T22:01:35.000Z","date":"2026-06-23","kind":"grant","planned":false,"acquired":true,"shares":7864,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted pursuant to the Issuer's 2025 Equity Incentive Plan (the \"Plan\"). The RSUs will vest in three equal annual installments beginning on June 23, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of voting common stock of the Issuer."}],"balance_after":7864,"source":{"system":"sec-edgar","filing":"0001435618-26-000011","document":"form4-06252026_100631.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000143561826000011/form4-06252026_100631.xml","form_type":"4"}},{"id":743015,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-06-10T20:15:10.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":38000,"derivative":{"exercise_price":3.94,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":38000},"source":{"system":"sec-edgar","filing":"0001435618-26-000006","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000143561826000006/primarydocument.xml","form_type":"4"}},{"id":929070,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-29T00:21:02.000Z","date":"2026-01-26","kind":"grant","planned":false,"acquired":true,"shares":745875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this option vest on January 26, 2027, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan) to the Issuer on each such vesting date."}],"balance_after":745875,"derivative":{"exercise_price":26.31,"expiration_date":"2036-01-25","underlying":"Common Stock","underlying_shares":745875},"source":{"system":"sec-edgar","filing":"0001435618-26-000003","document":"form4-01292026_120158.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000143561826000003/form4-01292026_120158.xml","form_type":"4"}},{"id":1011309,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-31T00:14:01.000Z","date":"2025-10-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":56400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 17, 2025, by and among 89bio, Inc. (the \"Issuer\"), Roche Holdings, Inc. (\"Parent\") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $14.50 per Share in cash, without interest (the \"Closing Amount\") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a \"CVR\") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an \"Out of the Money Option\"), [continues to Footnote 4]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":9.6,"expiration_date":"2035-02-01","underlying":"Common Stock","underlying_shares":56400},"source":{"system":"sec-edgar","filing":"0001193125-25-259040","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000119312525259040/ownership.xml","form_type":"4"}},{"id":1011308,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-31T00:14:01.000Z","date":"2025-10-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":67700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 17, 2025, by and among 89bio, Inc. (the \"Issuer\"), Roche Holdings, Inc. (\"Parent\") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $14.50 per Share in cash, without interest (the \"Closing Amount\") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a \"CVR\") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an \"Out of the Money Option\"), [continues to Footnote 4]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":8.86,"expiration_date":"2034-05-02","underlying":"Common Stock","underlying_shares":67700},"source":{"system":"sec-edgar","filing":"0001193125-25-259040","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000119312525259040/ownership.xml","form_type":"4"}},{"id":1078441,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-01T01:05:05.000Z","date":"2025-07-29","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares underlying this option vest on July 29, 2026, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan) to the Issuer on each such vesting date."}],"balance_after":150000,"derivative":{"exercise_price":3.95,"expiration_date":"2035-07-28","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001415889-25-020801","document":"form4-07312025_090701.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588925020801/form4-07312025_090701.xml","form_type":"4"}},{"id":1078440,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-01T01:05:05.000Z","date":"2025-07-29","kind":"grant","planned":false,"acquired":true,"shares":662000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares underlying this option vest on July 29, 2026, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan) to the Issuer on each such vesting date."}],"balance_after":662000,"derivative":{"exercise_price":3.95,"expiration_date":"2035-07-28","underlying":"Common Stock","underlying_shares":662000},"source":{"system":"sec-edgar","filing":"0001415889-25-020801","document":"form4-07312025_090701.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588925020801/form4-07312025_090701.xml","form_type":"4"}},{"id":1111463,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-06-13T20:13:01.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":38000,"derivative":{"exercise_price":1.04,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":38000},"source":{"system":"sec-edgar","filing":"0001562180-25-004786","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000156218025004786/primarydocument.xml","form_type":"4"}},{"id":1179925,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Common Stock","published_at":"2025-04-03T22:05:05.000Z","date":"2025-04-01","kind":"purchase","planned":false,"acquired":true,"shares":15650,"price":6.4366,"value":100732.79,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $6.18 to $6.95. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held directly by Martin Babler revocable trust UAD October 25, 2006, for which Reporting Person serves as a trustee."}],"balance_after":106454,"source":{"system":"sec-edgar","filing":"0001415889-25-010049","document":"form4-04032025_100402.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588925010049/form4-04032025_100402.xml","form_type":"4"}},{"id":1256002,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-20T23:30:05.000Z","date":"2025-02-18","kind":"grant","planned":false,"acquired":true,"shares":523000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this option vest on February 18, 2026, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":523000,"derivative":{"exercise_price":5.06,"expiration_date":"2035-02-17","underlying":"Common Stock","underlying_shares":523000},"source":{"system":"sec-edgar","filing":"0001415889-25-004936","document":"form4-02202025_060201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588925004936/form4-02202025_060201.xml","form_type":"4"}},{"id":1281705,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-05T21:01:07.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":56400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 56,400 shares of the Issuer's Common Stock, which will vest in full on February 1, 2026, subject to the Reporting Person's continued service to the Issuer through such date."}],"balance_after":56400,"derivative":{"exercise_price":9.6,"expiration_date":"2035-02-03","underlying":"Common Stock","underlying_shares":56400},"source":{"system":"sec-edgar","filing":"0000950170-25-014434","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000095017025014434/ownership.xml","form_type":"4"}},{"id":1465908,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:35:54.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":245989,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"25% of the shares underlying this option vest on June 6, 2025, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":245989,"derivative":{"exercise_price":13.33,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":245989},"source":{"system":"sec-edgar","filing":"0001415889-24-018589","document":"form4-07012024_080750.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018589/form4-07012024_080750.xml","form_type":"4"}},{"id":1465907,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:35:54.000Z","date":"2024-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":245989,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"25% of the shares underlying this option vest on June 6, 2025, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":13.33,"expiration_date":"2034-06-05","underlying":"Class A Common Stock","underlying_shares":245989},"source":{"system":"sec-edgar","filing":"0001415889-24-018589","document":"form4-07012024_080750.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018589/form4-07012024_080750.xml","form_type":"4"}},{"id":1465906,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:35:54.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":478288,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The option vests in three equal installments, subject to the Issuer's satisfaction of certain performance criteria on each of May 6, 2028, May 6, 2029 and May 6, 2030, and subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":478288,"derivative":{"exercise_price":10.2,"expiration_date":"2034-05-05","underlying":"Common Stock","underlying_shares":478288},"source":{"system":"sec-edgar","filing":"0001415889-24-018589","document":"form4-07012024_080750.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018589/form4-07012024_080750.xml","form_type":"4"}},{"id":1465905,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:35:54.000Z","date":"2024-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":478288,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The option vests in three equal installments, subject to the Issuer's satisfaction of certain performance criteria on each of May 6, 2028, May 6, 2029 and May 6, 2030, and subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":10.2,"expiration_date":"2034-05-05","underlying":"Class A Common Stock","underlying_shares":478288},"source":{"system":"sec-edgar","filing":"0001415889-24-018589","document":"form4-07012024_080750.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018589/form4-07012024_080750.xml","form_type":"4"}},{"id":1465904,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:35:54.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":241210,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"25% of the shares underlying this option vest on March 29, 2025, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":241210,"derivative":{"exercise_price":8.84,"expiration_date":"2034-03-28","underlying":"Common Stock","underlying_shares":241210},"source":{"system":"sec-edgar","filing":"0001415889-24-018589","document":"form4-07012024_080750.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018589/form4-07012024_080750.xml","form_type":"4"}},{"id":1465903,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:35:54.000Z","date":"2024-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":241210,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"25% of the shares underlying this option vest on March 29, 2025, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":8.84,"expiration_date":"2034-03-28","underlying":"Class A Common Stock","underlying_shares":241210},"source":{"system":"sec-edgar","filing":"0001415889-24-018589","document":"form4-07012024_080750.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018589/form4-07012024_080750.xml","form_type":"4"}},{"id":1465902,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:35:54.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":107028,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"25% of the shares underlying this option vest on October 9, 2024, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":107028,"derivative":{"exercise_price":8.84,"expiration_date":"2033-10-08","underlying":"Common Stock","underlying_shares":107028},"source":{"system":"sec-edgar","filing":"0001415889-24-018589","document":"form4-07012024_080750.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018589/form4-07012024_080750.xml","form_type":"4"}},{"id":1465901,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:35:54.000Z","date":"2024-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":107028,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"25% of the shares underlying this option vest on October 9, 2024, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":8.84,"expiration_date":"2033-10-08","underlying":"Class A Common Stock","underlying_shares":107028},"source":{"system":"sec-edgar","filing":"0001415889-24-018589","document":"form4-07012024_080750.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018589/form4-07012024_080750.xml","form_type":"4"}},{"id":1465900,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:35:54.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":263101,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares underlying this option vested on May 22, 2024, and the remaining shares vest n equal monthly installments thereafter over the following 36 months, subject to acceleration and subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":263101,"derivative":{"exercise_price":8.84,"expiration_date":"2033-06-22","underlying":"Common Stock","underlying_shares":263101},"source":{"system":"sec-edgar","filing":"0001415889-24-018589","document":"form4-07012024_080750.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018589/form4-07012024_080750.xml","form_type":"4"}},{"id":1465899,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:35:54.000Z","date":"2024-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":263101,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares underlying this option vested on May 22, 2024, and the remaining shares vest n equal monthly installments thereafter over the following 36 months, subject to acceleration and subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":8.84,"expiration_date":"2033-06-22","underlying":"Class A Common Stock","underlying_shares":263101},"source":{"system":"sec-edgar","filing":"0001415889-24-018589","document":"form4-07012024_080750.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018589/form4-07012024_080750.xml","form_type":"4"}},{"id":1465898,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:35:54.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":534759,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"33% of the shares underlying this option vested on January 27, 2024, and the remaining shares vest in equal monthly installments thereafter over the following 48 months, subject to acceleration and subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":534759,"derivative":{"exercise_price":8.84,"expiration_date":"2032-01-26","underlying":"Common Stock","underlying_shares":534759},"source":{"system":"sec-edgar","filing":"0001415889-24-018589","document":"form4-07012024_080750.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018589/form4-07012024_080750.xml","form_type":"4"}},{"id":1465897,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:35:54.000Z","date":"2024-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":534759,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"33% of the shares underlying this option vested on January 27, 2024, and the remaining shares vest in equal monthly installments thereafter over the following 48 months, subject to acceleration and subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":8.84,"expiration_date":"2032-01-26","underlying":"Class A Common Stock","underlying_shares":534759},"source":{"system":"sec-edgar","filing":"0001415889-24-018589","document":"form4-07012024_080750.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018589/form4-07012024_080750.xml","form_type":"4"}},{"id":1465896,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:35:54.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":106951,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares underlying this option vested on January 27, 2023, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":106951,"derivative":{"exercise_price":8.84,"expiration_date":"2032-01-26","underlying":"Common Stock","underlying_shares":106951},"source":{"system":"sec-edgar","filing":"0001415889-24-018589","document":"form4-07012024_080750.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018589/form4-07012024_080750.xml","form_type":"4"}},{"id":1465895,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:35:54.000Z","date":"2024-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":106951,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares underlying this option vested on January 27, 2023, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":8.84,"expiration_date":"2032-01-26","underlying":"Class A Common Stock","underlying_shares":106951},"source":{"system":"sec-edgar","filing":"0001415889-24-018589","document":"form4-07012024_080750.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018589/form4-07012024_080750.xml","form_type":"4"}},{"id":1465894,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:35:54.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":380852,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares underlying this option vested on September 15, 2022, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and subject to the Reporting Person's continuous service to the Issuer on each such vesting date.  This option was originally granted in the amount of 3,000,000 shares and was subsequently partially exercised for 1,219,513 shares on October 22, 2021."}],"balance_after":380852,"derivative":{"exercise_price":3.84,"expiration_date":"2031-09-14","underlying":"Common Stock","underlying_shares":380852},"source":{"system":"sec-edgar","filing":"0001415889-24-018589","document":"form4-07012024_080750.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018589/form4-07012024_080750.xml","form_type":"4"}},{"id":1465893,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:35:54.000Z","date":"2024-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":380852,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares underlying this option vested on September 15, 2022, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and subject to the Reporting Person's continuous service to the Issuer on each such vesting date.  This option was originally granted in the amount of 3,000,000 shares and was subsequently partially exercised for 1,219,513 shares on October 22, 2021."}],"balance_after":0,"derivative":{"exercise_price":3.84,"expiration_date":"2031-09-14","underlying":"Class A Common Stock","underlying_shares":380852},"source":{"system":"sec-edgar","filing":"0001415889-24-018589","document":"form4-07012024_080750.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018589/form4-07012024_080750.xml","form_type":"4"}},{"id":1465892,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:35:54.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":21390,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares underlying this option vest on June 21, 2025, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":21390,"derivative":{"exercise_price":16,"expiration_date":"2034-06-26","underlying":"Common Stock","underlying_shares":21390},"source":{"system":"sec-edgar","filing":"0001415889-24-018589","document":"form4-07012024_080750.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018589/form4-07012024_080750.xml","form_type":"4"}},{"id":1465891,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:35:54.000Z","date":"2024-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":21390,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares underlying this option vest on June 21, 2025, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2034-06-26","underlying":"Class A Common Stock","underlying_shares":21390},"source":{"system":"sec-edgar","filing":"0001415889-24-018589","document":"form4-07012024_080750.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018589/form4-07012024_080750.xml","form_type":"4"}},{"id":1465890,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:35:54.000Z","date":"2024-06-27","kind":"grant","planned":false,"acquired":true,"shares":21390,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares underlying this option vest on June 21, 2025, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":21390,"derivative":{"exercise_price":16,"expiration_date":"2034-06-26","underlying":"Class A Common Stock","underlying_shares":21390},"source":{"system":"sec-edgar","filing":"0001415889-24-018589","document":"form4-07012024_080750.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018589/form4-07012024_080750.xml","form_type":"4"}},{"id":1465889,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Common Stock","published_at":"2024-07-01T20:35:54.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":90804,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held directly by Martin Babler revocable trust UAD October 25, 2006, for which Reporting Person serves as a trustee."}],"balance_after":90804,"source":{"system":"sec-edgar","filing":"0001415889-24-018589","document":"form4-07012024_080750.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018589/form4-07012024_080750.xml","form_type":"4"}},{"id":1465888,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Class A Common Stock","published_at":"2024-07-01T20:35:54.000Z","date":"2024-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":90804,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held directly by Martin Babler revocable trust UAD October 25, 2006, for which Reporting Person serves as a trustee."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-24-018589","document":"form4-07012024_080750.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018589/form4-07012024_080750.xml","form_type":"4"}},{"id":1475086,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2024-06-18T20:11:52.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":23500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":23500,"derivative":{"exercise_price":3.9,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":23500},"source":{"system":"sec-edgar","filing":"0001562180-24-005159","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000156218024005159/primarydocument.xml","form_type":"4"}},{"id":1527976,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-03T20:01:06.000Z","date":"2024-05-02","kind":"grant","planned":false,"acquired":true,"shares":67700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 67,700 shares of the Issuer's Common Stock, which vests in equal installments on April 13, 2025, April 13, 2026 and April 13, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":67700,"derivative":{"exercise_price":8.86,"expiration_date":"2034-05-02","underlying":"Common Stock","underlying_shares":67700},"source":{"system":"sec-edgar","filing":"0000950170-24-052857","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000095017024052857/ownership.xml","form_type":"4"}},{"id":1847718,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2023-06-21T20:11:58.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":23500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":23500,"derivative":{"exercise_price":5.56,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":23500},"source":{"system":"sec-edgar","filing":"0001209191-23-038770","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919123038770/doc4.xml","form_type":"4"}},{"id":1860400,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-09T20:24:41.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the total shares monthly beginning July 8, 2023 until the option is fully vested on June 8, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":25000,"derivative":{"exercise_price":0.79,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-23-035853","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919123035853/doc4.xml","form_type":"4"}},{"id":2224049,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2022-06-22T20:13:43.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":31293,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":31293,"derivative":{"exercise_price":4.74,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":31293},"source":{"system":"sec-edgar","filing":"0001562180-22-005296","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000156218022005296/primarydocument.xml","form_type":"4"}},{"id":2270207,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-16T22:22:00.000Z","date":"2022-05-12","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the total shares monthly beginning June 12, 2022 until the option is fully vested on May 12, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":25000,"derivative":{"exercise_price":1.07,"expiration_date":"2032-05-11","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-22-029321","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919122029321/doc4.xml","form_type":"4"}},{"id":2629170,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-07-21T00:30:41.000Z","date":"2021-07-19","kind":"grant","acquired":true,"shares":36400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vested as to 1/36 of the total shares monthly beginning on August 19, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":36400,"derivative":{"exercise_price":31.37,"expiration_date":"2031-07-18","underlying":"Common Stock","underlying_shares":36400},"source":{"system":"sec-edgar","filing":"0001209191-21-047500","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919121047500/doc4.xml","form_type":"4"}},{"id":2714337,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-13T21:36:52.000Z","date":"2021-05-11","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the total shares monthly beginning June 11, 2021 until the option is fully vested on May 11, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":25000,"derivative":{"exercise_price":11.4,"expiration_date":"2031-05-10","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-21-032397","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919121032397/doc4.xml","form_type":"4"}},{"id":3021676,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-09-28T21:07:12.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":67.31,"expiration_date":"2030-03-04","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001209191-20-052222","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919120052222/doc4.xml","form_type":"4"}},{"id":3021675,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-09-28T21:07:12.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":155000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":35.42,"expiration_date":"2029-02-28","underlying":"Common Stock","underlying_shares":155000},"source":{"system":"sec-edgar","filing":"0001209191-20-052222","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919120052222/doc4.xml","form_type":"4"}},{"id":3021674,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-09-28T21:07:12.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":187144,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":11.3549,"expiration_date":"2028-08-23","underlying":"Common Stock","underlying_shares":187144},"source":{"system":"sec-edgar","filing":"0001209191-20-052222","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919120052222/doc4.xml","form_type":"4"}},{"id":3021673,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-09-28T21:07:12.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":115590,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":7.2671,"expiration_date":"2027-12-13","underlying":"Common Stock","underlying_shares":115590},"source":{"system":"sec-edgar","filing":"0001209191-20-052222","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919120052222/doc4.xml","form_type":"4"}},{"id":3021672,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-09-28T21:07:12.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":60546,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":4.9961,"expiration_date":"2025-07-20","underlying":"Common Stock","underlying_shares":60546},"source":{"system":"sec-edgar","filing":"0001209191-20-052222","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919120052222/doc4.xml","form_type":"4"}},{"id":3021671,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-09-28T21:07:12.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":83004,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":4.7236,"expiration_date":"2024-12-25","underlying":"Common Stock","underlying_shares":83004},"source":{"system":"sec-edgar","filing":"0001209191-20-052222","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919120052222/doc4.xml","form_type":"4"}},{"id":3021670,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-09-28T21:07:12.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":110085,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":3.1794,"expiration_date":"2024-06-26","underlying":"Common Stock","underlying_shares":110085},"source":{"system":"sec-edgar","filing":"0001209191-20-052222","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919120052222/doc4.xml","form_type":"4"}},{"id":3021669,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-09-28T21:07:12.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":85728,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":2.9977,"expiration_date":"2023-10-23","underlying":"Common Stock","underlying_shares":85728},"source":{"system":"sec-edgar","filing":"0001209191-20-052222","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919120052222/doc4.xml","form_type":"4"}},{"id":3021668,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-09-28T21:07:12.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":50795,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":1.9076,"expiration_date":"2022-07-02","underlying":"Common Stock","underlying_shares":50795},"source":{"system":"sec-edgar","filing":"0001209191-20-052222","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919120052222/doc4.xml","form_type":"4"}},{"id":3021667,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Warrant (Right to Buy)","published_at":"2020-09-28T21:07:12.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":255,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each warrant was converted into the right to receive $100.00 less the applicable exercise price per share of such warrant."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each warrant was converted into the right to receive $100.00 less the applicable exercise price per share of such warrant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each warrant was converted into the right to receive $100.00 less the applicable exercise price per share of such warrant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares indirectly held by Martin Babler, as custodian for his minor children under California Uniform Transfer to Minors Act, of which the Reporting Person is a custodian and may be deemed to share voting and dispositive power over these shares."}],"balance_after":0,"derivative":{"exercise_price":8.9931,"expiration_date":"2022-12-29","underlying":"Common Stock","underlying_shares":255},"source":{"system":"sec-edgar","filing":"0001209191-20-052222","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919120052222/doc4.xml","form_type":"4"}},{"id":3021666,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2020-09-28T21:07:12.000Z","date":"2020-09-28","kind":"other","acquired":false,"shares":18355,"price":100,"value":1835500.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the \"Issuer\"), Sanofi (\"Sanofi\") and Kortex Acquisition Corp. (\"Purchaser\") (the \"Merger Agreement\"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), these shares were canceled in exchange for $100.00 per share in cash, without interest and subject to any applicable withholding taxes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares indirectly held by Martin Babler, as custodian for his minor children under California Uniform Transfer to Minors Act, of which the Reporting Person is a custodian and may be deemed to share voting and dispositive power over these shares."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-052222","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919120052222/doc4.xml","form_type":"4"}},{"id":3021665,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2020-09-28T21:07:12.000Z","date":"2020-09-28","kind":"other","acquired":false,"shares":39179,"price":100,"value":3917900.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the \"Issuer\"), Sanofi (\"Sanofi\") and Kortex Acquisition Corp. (\"Purchaser\") (the \"Merger Agreement\"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), these shares were canceled in exchange for $100.00 per share in cash, without interest and subject to any applicable withholding taxes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares indirectly held by Babler Trust Agreement Dated October 25, 2006, of which the Reporting Person is a trustee and may be deemed to share voting and dispositive power over these shares."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-052222","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919120052222/doc4.xml","form_type":"4"}},{"id":3021664,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2020-09-28T21:07:12.000Z","date":"2020-09-28","kind":"other","acquired":false,"shares":1023,"price":100,"value":102300.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the \"Issuer\"), Sanofi (\"Sanofi\") and Kortex Acquisition Corp. (\"Purchaser\") (the \"Merger Agreement\"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), these shares were canceled in exchange for $100.00 per share in cash, without interest and subject to any applicable withholding taxes."},{"field":"shares","element":"transactionShares","label":"F2","text":"Includes 213 shares acquired under the Employment Stock Purchase Plan on September 25, 2020."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-052222","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919120052222/doc4.xml","form_type":"4"}},{"id":3034327,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-09-10T20:28:07.000Z","date":"2020-09-08","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/3 of the total shares on each of September 8, 2021, September 8, 2022 and September 8, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":50000,"derivative":{"exercise_price":12.25,"expiration_date":"2030-09-08","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-20-049966","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919120049966/doc4.xml","form_type":"4"}},{"id":3099710,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-06-26T00:07:54.000Z","date":"2020-06-23","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The stock option is fully vested and immediately exercisable."}],"balance_after":85728,"derivative":{"exercise_price":2.9977,"expiration_date":"2023-10-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-20-039026","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919120039026/doc4.xml","form_type":"4"}},{"id":3099709,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2020-06-26T00:07:54.000Z","date":"2020-06-23","kind":"sale","acquired":false,"shares":2502,"price":62.3812,"value":156077.7624,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $62.137 to $62.52 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":810,"source":{"system":"sec-edgar","filing":"0001209191-20-039026","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919120039026/doc4.xml","form_type":"4"}},{"id":3099708,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2020-06-26T00:07:54.000Z","date":"2020-06-23","kind":"sale","acquired":false,"shares":11983,"price":61.8163,"value":740744.7229,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $61.12 to $62.115 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":3312,"source":{"system":"sec-edgar","filing":"0001209191-20-039026","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919120039026/doc4.xml","form_type":"4"}},{"id":3099707,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2020-06-26T00:07:54.000Z","date":"2020-06-23","kind":"sale","acquired":false,"shares":515,"price":60.3225,"value":31066.0875,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $60.00 to $60.75 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":15295,"source":{"system":"sec-edgar","filing":"0001209191-20-039026","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919120039026/doc4.xml","form_type":"4"}},{"id":3099706,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2020-06-26T00:07:54.000Z","date":"2020-06-23","kind":"exercise","acquired":true,"shares":15000,"price":2.9977,"value":44965.5,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 810 shares acquired under the Employment Stock Purchase Plan on May 15, 2020."}],"balance_after":15810,"source":{"system":"sec-edgar","filing":"0001209191-20-039026","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919120039026/doc4.xml","form_type":"4"}},{"id":3224448,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-03-05T22:21:55.000Z","date":"2020-03-05","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The stock option vests and becomes exercisable as to 25% of the shares subject to the option on March 5, 2021, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":200000,"derivative":{"exercise_price":67.31,"expiration_date":"2030-03-04","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001209191-20-016684","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919120016684/doc4.xml","form_type":"4"}},{"id":3224447,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2020-03-05T22:21:55.000Z","date":"2020-03-03","kind":"sale","acquired":false,"shares":300,"price":64.8267,"value":19448.01,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $64.78 to $64.90 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares indirectly held by Babler Trust Agreement Dated October 25, 2006, of which the Reporting Person is a trustee and may be deemed to share voting and dispositive power over these shares."}],"balance_after":39179,"source":{"system":"sec-edgar","filing":"0001209191-20-016684","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919120016684/doc4.xml","form_type":"4"}},{"id":3224446,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2020-03-05T22:21:55.000Z","date":"2020-03-03","kind":"sale","acquired":false,"shares":5432,"price":64.098,"value":348180.336,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $63.75 to $64.695 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares indirectly held by Babler Trust Agreement Dated October 25, 2006, of which the Reporting Person is a trustee and may be deemed to share voting and dispositive power over these shares."}],"balance_after":39479,"source":{"system":"sec-edgar","filing":"0001209191-20-016684","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919120016684/doc4.xml","form_type":"4"}},{"id":3224445,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2020-03-05T22:21:55.000Z","date":"2020-03-03","kind":"sale","acquired":false,"shares":7183,"price":63.2398,"value":454251.4834,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $62.74 to $63.725 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares indirectly held by Babler Trust Agreement Dated October 25, 2006, of which the Reporting Person is a trustee and may be deemed to share voting and dispositive power over these shares."}],"balance_after":44911,"source":{"system":"sec-edgar","filing":"0001209191-20-016684","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919120016684/doc4.xml","form_type":"4"}},{"id":3224444,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2020-03-05T22:21:55.000Z","date":"2020-03-03","kind":"sale","acquired":false,"shares":2085,"price":62.4476,"value":130203.246,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $61.74 to $62.735 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares indirectly held by Babler Trust Agreement Dated October 25, 2006, of which the Reporting Person is a trustee and may be deemed to share voting and dispositive power over these shares."}],"balance_after":52094,"source":{"system":"sec-edgar","filing":"0001209191-20-016684","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919120016684/doc4.xml","form_type":"4"}},{"id":3224443,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2020-03-05T22:21:55.000Z","date":"2020-02-10","kind":"gift","acquired":true,"shares":1159,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were gifted to three accounts held in trust for each of Martin Babler's minor children."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares indirectly held by Martin Babler, as custodian for his minor children under California Uniform Transfer to Minors Act, of which the Reporting Person is a custodian and may be deemed to share voting and dispositive power over these shares."}],"balance_after":18355,"source":{"system":"sec-edgar","filing":"0001209191-20-016684","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919120016684/doc4.xml","form_type":"4"}},{"id":3224442,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2020-03-05T22:21:55.000Z","date":"2020-02-10","kind":"gift","acquired":false,"shares":1159,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-016684","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919120016684/doc4.xml","form_type":"4"}},{"id":3270471,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2020-02-14T22:58:42.000Z","date":"2019-12-27","kind":"gift","acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were gifted in equal amounts to three accounts held in trust for each of Martin Babler's minor children."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares indirectly held by Martin Babler, as custodian for his minor children under California Uniform Transfer to Minor Act, of which the Reporting Person is a custodian and may be deemed to share voting and dispositive power over these shares."}],"balance_after":17196,"source":{"system":"sec-edgar","filing":"0001209191-20-009769","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919120009769/doc5.xml","form_type":"5"}},{"id":3270470,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2020-02-14T22:58:42.000Z","date":"2019-12-27","kind":"gift","acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1159,"source":{"system":"sec-edgar","filing":"0001209191-20-009769","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919120009769/doc5.xml","form_type":"5"}},{"id":3335138,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2019-12-20T02:06:03.000Z","date":"2019-12-18","kind":"sale","acquired":false,"shares":1295,"price":54.2799,"value":70292.4705,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $54.13 to $54.42 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Sales were sold in equal amounts in a block trade aggregated from three accounts held in trust for each of Mr. Babler's minor children."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Shares indirectly held by Martin Babler, as custodian for his minor children under California Uniform Transfer to Minor Act, of which the Reporting Person is a custodian and may be deemed to share voting and dispositive power over these shares."}],"balance_after":15696,"source":{"system":"sec-edgar","filing":"0001209191-19-061423","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919119061423/doc4.xml","form_type":"4"}},{"id":3335137,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2019-12-20T02:06:03.000Z","date":"2019-12-18","kind":"sale","acquired":false,"shares":2205,"price":53.6926,"value":118392.183,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $53.13 to $54.105 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Sales were sold in equal amounts in a block trade aggregated from three accounts held in trust for each of Mr. Babler's minor children."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Shares indirectly held by Martin Babler, as custodian for his minor children under California Uniform Transfer to Minor Act, of which the Reporting Person is a custodian and may be deemed to share voting and dispositive power over these shares."}],"balance_after":16991,"source":{"system":"sec-edgar","filing":"0001209191-19-061423","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919119061423/doc4.xml","form_type":"4"}},{"id":3335136,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2019-12-20T02:06:03.000Z","date":"2019-12-18","kind":"sale","acquired":false,"shares":1000,"price":52.7747,"value":52774.7,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $52.10 to $53.04 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Sales were sold in equal amounts in a block trade aggregated from three accounts held in trust for each of Mr. Babler's minor children."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Shares indirectly held by Martin Babler, as custodian for his minor children under California Uniform Transfer to Minor Act, of which the Reporting Person is a custodian and may be deemed to share voting and dispositive power over these shares."}],"balance_after":19196,"source":{"system":"sec-edgar","filing":"0001209191-19-061423","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919119061423/doc4.xml","form_type":"4"}},{"id":3335135,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2019-12-20T02:06:03.000Z","date":"2019-12-17","kind":"sale","acquired":false,"shares":1014,"price":54.355,"value":55115.97,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $54.31 to $54.47 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares indirectly held by Babler Trust Agreement Dated October 25, 2006, of which the Reporting Person is a trustee and may be deemed to share voting and dispositive power over these shares."}],"balance_after":54179,"source":{"system":"sec-edgar","filing":"0001209191-19-061423","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919119061423/doc4.xml","form_type":"4"}},{"id":3335134,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2019-12-20T02:06:03.000Z","date":"2019-12-17","kind":"sale","acquired":false,"shares":6661,"price":53.9429,"value":359313.6569,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $53.30 to $54.29 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares indirectly held by Babler Trust Agreement Dated October 25, 2006, of which the Reporting Person is a trustee and may be deemed to share voting and dispositive power over these shares."}],"balance_after":55193,"source":{"system":"sec-edgar","filing":"0001209191-19-061423","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919119061423/doc4.xml","form_type":"4"}},{"id":3335133,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2019-12-20T02:06:03.000Z","date":"2019-12-17","kind":"sale","acquired":false,"shares":11485,"price":52.8571,"value":607063.7935,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $52.30 to $53.28 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares indirectly held by Babler Trust Agreement Dated October 25, 2006, of which the Reporting Person is a trustee and may be deemed to share voting and dispositive power over these shares."}],"balance_after":61854,"source":{"system":"sec-edgar","filing":"0001209191-19-061423","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919119061423/doc4.xml","form_type":"4"}},{"id":3335132,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2019-12-20T02:06:03.000Z","date":"2019-12-17","kind":"sale","acquired":false,"shares":5840,"price":51.7983,"value":302502.072,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $51.29 to $52.26 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares indirectly held by Babler Trust Agreement Dated October 25, 2006, of which the Reporting Person is a trustee and may be deemed to share voting and dispositive power over these shares."}],"balance_after":73339,"source":{"system":"sec-edgar","filing":"0001209191-19-061423","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919119061423/doc4.xml","form_type":"4"}},{"id":3604217,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-03-08T22:31:23.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":155000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable as to 25% of the shares subject to the option on March 1, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":155000,"derivative":{"exercise_price":35.42,"expiration_date":"2029-02-28","underlying":"Common Stock","underlying_shares":155000},"source":{"system":"sec-edgar","filing":"0001209191-19-018215","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919119018215/doc4.xml","form_type":"4"}},{"id":3810614,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series C Preferred Stock","published_at":"2018-09-20T22:45:09.000Z","date":"2018-09-18","kind":"exercise","acquired":false,"shares":240,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock automatically converted into one (1) share of Common Stock, for no additional consideration, upon the consummation of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Preferred Stock automatically converted into one (1) share of Common Stock, for no additional consideration, upon the consummation of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock automatically converted into one (1) share of Common Stock, for no additional consideration, upon the consummation of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock automatically converted into one (1) share of Common Stock, for no additional consideration, upon the consummation of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares indirectly held by Martin Babler, as Custodian for Natalie Flurina Babler-Kuebler, under California Uniform Transfer to Minor Act, of which the Reporting Person is a cusstodian and may be deemed to share voting and dispositive power over these shares."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":240},"source":{"system":"sec-edgar","filing":"0001209191-18-051828","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919118051828/doc4.xml","form_type":"4"}},{"id":3810613,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series C Preferred Stock","published_at":"2018-09-20T22:45:09.000Z","date":"2018-09-18","kind":"exercise","acquired":false,"shares":240,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock automatically converted into one (1) share of Common Stock, for no additional consideration, upon the consummation of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Preferred Stock automatically converted into one (1) share of Common Stock, for no additional consideration, upon the consummation of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock automatically converted into one (1) share of Common Stock, for no additional consideration, upon the consummation of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock automatically converted into one (1) share of Common Stock, for no additional consideration, upon the consummation of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares indirectly held by Martin Babler, as Custodian for Justin Alexander Babler-Kuebler, under California Uniform Transfer to Minor Act, of which the Reporting Person is a custodian and may be deemed to share voting and dispositive power over these shares."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":240},"source":{"system":"sec-edgar","filing":"0001209191-18-051828","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919118051828/doc4.xml","form_type":"4"}},{"id":3810612,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series C Preferred Stock","published_at":"2018-09-20T22:45:09.000Z","date":"2018-09-18","kind":"exercise","acquired":false,"shares":240,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock automatically converted into one (1) share of Common Stock, for no additional consideration, upon the consummation of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Preferred Stock automatically converted into one (1) share of Common Stock, for no additional consideration, upon the consummation of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock automatically converted into one (1) share of Common Stock, for no additional consideration, upon the consummation of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock automatically converted into one (1) share of Common Stock, for no additional consideration, upon the consummation of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares indirectly held by Martin Babler, as Custodian for Angelina Veronique Babler-Kuebler, under California Uniform Transfer to Minor Act, of which the Reporting Person is a custodian and may be deemed to share voting and dispositive power over these shares."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":240},"source":{"system":"sec-edgar","filing":"0001209191-18-051828","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919118051828/doc4.xml","form_type":"4"}},{"id":3810611,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series B-3 Preferred Stock","published_at":"2018-09-20T22:45:09.000Z","date":"2018-09-18","kind":"exercise","acquired":false,"shares":988,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock automatically converted into one (1) share of Common Stock, for no additional consideration, upon the consummation of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Preferred Stock automatically converted into one (1) share of Common Stock, for no additional consideration, upon the consummation of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock automatically converted into one (1) share of Common Stock, for no additional consideration, upon the consummation of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock automatically converted into one (1) share of Common Stock, for no additional consideration, upon the consummation of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares indirectly held by Martin Babler, as Custodian for Natalie Flurina Babler-Kuebler, under California Uniform Transfer to Minor Act, of which the Reporting Person is a cusstodian and may be deemed to share voting and dispositive power over these shares."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":988},"source":{"system":"sec-edgar","filing":"0001209191-18-051828","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919118051828/doc4.xml","form_type":"4"}},{"id":3810610,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series B-3 Preferred Stock","published_at":"2018-09-20T22:45:09.000Z","date":"2018-09-18","kind":"exercise","acquired":false,"shares":988,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock automatically converted into one (1) share of Common Stock, for no additional consideration, upon the consummation of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Preferred Stock automatically converted into one (1) share of Common Stock, for no additional consideration, upon the consummation of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock automatically converted into one (1) share of Common Stock, for no additional consideration, upon the consummation of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock automatically converted into one (1) share of Common Stock, for no additional consideration, upon the consummation of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares indirectly held by Martin Babler, as Custodian for Justin Alexander Babler-Kuebler, under California Uniform Transfer to Minor Act, of which the Reporting Person is a custodian and may be deemed to share voting and dispositive power over these shares."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":988},"source":{"system":"sec-edgar","filing":"0001209191-18-051828","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919118051828/doc4.xml","form_type":"4"}},{"id":3810609,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series B-3 Preferred Stock","published_at":"2018-09-20T22:45:09.000Z","date":"2018-09-18","kind":"exercise","acquired":false,"shares":988,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock automatically converted into one (1) share of Common Stock, for no additional consideration, upon the consummation of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Preferred Stock automatically converted into one (1) share of Common Stock, for no additional consideration, upon the consummation of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock automatically converted into one (1) share of Common Stock, for no additional consideration, upon the consummation of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock automatically converted into one (1) share of Common Stock, for no additional consideration, upon the consummation of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares indirectly held by Martin Babler, as Custodian for Angelina Veronique Babler-Kuebler, under California Uniform Transfer to Minor Act, of which the Reporting Person is a custodian and may be deemed to share voting and dispositive power over these shares."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":988},"source":{"system":"sec-edgar","filing":"0001209191-18-051828","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919118051828/doc4.xml","form_type":"4"}},{"id":3810608,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-09-20T22:45:09.000Z","date":"2018-09-18","kind":"exercise","acquired":true,"shares":240,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Preferred Stock automatically converted into one (1) share of Common Stock, for no additional consideration, upon the consummation of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares indirectly held by Martin Babler, as Custodian for Natalie Flurina Babler-Kuebler, under California Uniform Transfer to Minor Act, of which the Reporting Person is a cusstodian and may be deemed to share voting and dispositive power over these shares."}],"balance_after":6732,"source":{"system":"sec-edgar","filing":"0001209191-18-051828","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919118051828/doc4.xml","form_type":"4"}},{"id":3810607,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-09-20T22:45:09.000Z","date":"2018-09-18","kind":"exercise","acquired":true,"shares":988,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Preferred Stock automatically converted into one (1) share of Common Stock, for no additional consideration, upon the consummation of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares indirectly held by Martin Babler, as Custodian for Natalie Flurina Babler-Kuebler, under California Uniform Transfer to Minor Act, of which the Reporting Person is a cusstodian and may be deemed to share voting and dispositive power over these shares."}],"balance_after":6492,"source":{"system":"sec-edgar","filing":"0001209191-18-051828","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919118051828/doc4.xml","form_type":"4"}},{"id":3810606,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-09-20T22:45:09.000Z","date":"2018-09-18","kind":"exercise","acquired":true,"shares":240,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Preferred Stock automatically converted into one (1) share of Common Stock, for no additional consideration, upon the consummation of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares indirectly held by Martin Babler, as Custodian for Justin Alexander Babler-Kuebler, under California Uniform Transfer to Minor Act, of which the Reporting Person is a custodian and may be deemed to share voting and dispositive power over these shares."}],"balance_after":6732,"source":{"system":"sec-edgar","filing":"0001209191-18-051828","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919118051828/doc4.xml","form_type":"4"}},{"id":3810605,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-09-20T22:45:09.000Z","date":"2018-09-18","kind":"exercise","acquired":true,"shares":988,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Preferred Stock automatically converted into one (1) share of Common Stock, for no additional consideration, upon the consummation of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares indirectly held by Martin Babler, as Custodian for Justin Alexander Babler-Kuebler, under California Uniform Transfer to Minor Act, of which the Reporting Person is a custodian and may be deemed to share voting and dispositive power over these shares."}],"balance_after":6492,"source":{"system":"sec-edgar","filing":"0001209191-18-051828","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919118051828/doc4.xml","form_type":"4"}},{"id":3810604,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-09-20T22:45:09.000Z","date":"2018-09-18","kind":"exercise","acquired":true,"shares":240,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Preferred Stock automatically converted into one (1) share of Common Stock, for no additional consideration, upon the consummation of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares indirectly held by Martin Babler, as Custodian for Angelina Veronique Babler-Kuebler, under California Uniform Transfer to Minor Act, of which the Reporting Person is a custodian and may be deemed to share voting and dispositive power over these shares."}],"balance_after":6732,"source":{"system":"sec-edgar","filing":"0001209191-18-051828","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919118051828/doc4.xml","form_type":"4"}},{"id":3810603,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":35360,"kind":"person","name":"Babler Martin","position":1,"cik":"0001435618","reported_name":"Babler Martin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-09-20T22:45:09.000Z","date":"2018-09-18","kind":"exercise","acquired":true,"shares":988,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Preferred Stock automatically converted into one (1) share of Common Stock, for no additional consideration, upon the consummation of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares indirectly held by Martin Babler, as Custodian for Angelina Veronique Babler-Kuebler, under California Uniform Transfer to Minor Act, of which the Reporting Person is a custodian and may be deemed to share voting and dispositive power over these shares."}],"balance_after":6492,"source":{"system":"sec-edgar","filing":"0001209191-18-051828","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435618/000120919118051828/doc4.xml","form_type":"4"}}]}